Tirzepatide vs Cagrilintide
A comparison of Tirzepatide and Cagrilintide in metabolic and weight research, including receptor targets, mechanism differences, and current evidence.
A comparison of Tirzepatide and Cagrilintide in metabolic and weight research, including receptor targets, mechanism differences, and current evidence.
Overview
Tirzepatide and Cagrilintide represent different approaches to metabolic intervention. Tirzepatide is a dual GIP/GLP-1 receptor agonist with an established clinical evidence base, while Cagrilintide is a long-acting amylin analog studied for its complementary mechanism in satiety and weight regulation, including in combination with Semaglutide in the CagriSema trial program.
Mechanism Comparison
Tirzepatide works primarily through the incretin axis, activating both GLP-1 and GIP receptors to regulate insulin secretion, satiety, and gastric emptying. Cagrilintide acts through amylin receptors, which are separate from the incretin pathway, producing satiety through a different neurological mechanism. This mechanistic distinction makes Cagrilintide more interesting as a complement to GLP-1 compounds than as a direct substitute.
Dosing and Protocol Comparison
Tirzepatide is studied at weekly subcutaneous doses in a titration protocol from 2.5 mg to 15 mg. Cagrilintide is studied at weekly doses from 0.3 mg to 4.5 mg as a monotherapy or in the CagriSema combination. Because their mechanisms are complementary rather than overlapping, the more meaningful protocol comparison is Tirzepatide monotherapy versus CagriSema combination rather than Tirzepatide versus Cagrilintide alone.
Evidence Comparison
Tirzepatide has a substantially more mature evidence base including the SURMOUNT and SURPASS trial programs with strong weight and glycemic outcome data. Cagrilintide is newer in clinical development, with most published data coming from the CagriSema combination trial program. Head-to-head evidence between these two compounds specifically is limited, as they target different metabolic axes.